Morpholine → 2,6-dimethyl-N-[(7-methyl-7-azabicyclo[2.2.1]heptan-1-yl)-(3-morpholin-4-ylphenyl)methyl]benzamide

HRID 642Notes

Reaction equation

HRID 642 reaction equation
C1COCCN1.Cc1cccc(C)c1C(=O)NC(c1cccc(Br)c1)C12CCC(CC1)N2C>CC(=O)O.CC(=O)O.CC(C)(C)[O-].Cc1ccccc1.[Na+].[Pd].c1ccc(P(c2ccccc2)c2ccc3ccccc3c2-c2c(P(c3ccccc3)c3ccccc3)ccc3ccccc23)cc1>Cc1cccc(C)c1C(=O)NC(c1cccc(N2CCOCC2)c1)C12CCC(CC1)N2C

Participants

7

Conditions

Temperature
80 °C

Procedure

To a suspension of N-((3-bromophenyl)(7-methyl-7-azabicyclo[2.2.1]heptan-1-yl)methyl)-2,6-dimethylbenzamide (0.040 g, 0.09 mmol), MORPHOLINE (8.97 µL, 0.10 mmol), BINAP (5.83 mg, 9.36 µmol), and sodium tert-butoxide (0.013 g, 0.14 mmol) in toluene (2 mL) was added palladium(II) acetate (1.051 mg, 4.68 µmol). Nitrogen was passed through the solution for 15 min prior to being heated at 80 °C overnight. Crude LC shows starting material still present. Heated to 110oC for 2 days. Reaqction no longer progressing. Reaction mixture was concentrated in vacuo. Material was diluted with ethyl acetate, filtered thru celite and concentrated in vacuo. Submitted to purification group (52 mg in 1.6 mL DMSO). Received back dried- down fractions. Diluted with DCM, combined and concentrated to afford 2,6-dimethyl-N-((7-methyl-7-azabicyclo[2.2.1]heptan-1-yl)(3-morpholinophenyl)methyl)benzamide (7.30 mg, 17.99 %) Submitted 4.5 mg Vial # 26243972 (TWOC): 7.0545 g

Sources & evidence

ORD record
ord-4e29f7f8d4e94f93bbf63ba519f77a6e
Source dataset
750 AstraZeneca ELN dataset
Original link
View source

Reaction notes

Loading…